Compare Medpace Holdings Inc (MEDP) vs Vanguard Emerging Markets Stock Index Fund ETF (VWO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Medpace Holdings Inc vs Vanguard Emerging Markets Stock Index Fund ETF — how do they compare? Medpace Holdings Inc trades at $611.57 (market cap $16.82B), while Vanguard Emerging Markets Stock Index Fund ETF trades at $59.74 (market cap $168.50B). The key difference: Vanguard Emerging Markets Stock Index Fund ETF is far larger — about 10× Medpace Holdings Inc's market cap, and Medpace Holdings Inc is trading nearer its 52-week high, Vanguard Emerging Markets Stock Index Fund ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Medpace Holdings Inc for 14 Days and Vanguard Emerging Markets Stock Index Fund ETF for 135 Days on average.
| MEDP | VWO | |
|---|---|---|
Market Cap | $16.82B | $168.50B |
Volume | 223,093 | 9,650,999 |
Sector | Health | — |
52-Week High | $630.19 | $61.44 |
52-Week Low | $393.42 | $52.42 |
Typical Hold Time | 14 Days | 135 Days |
Enterprise Value | $16.44B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Medpace (MEDP) trades at $617.47, up 2.19% with strong quarterly earnings beats and robust profitability metrics. The stock shows neutral technical signals with key resistance at $620, while fundamentals reveal impressive ROE of 162.15% and consistent revenue growth to $2.8B projected for 2026. Recent CEO stock sales and mixed institutional activity create balanced sentiment ahead of Q3 earnings announcement on October 21, 2026.
MEDP presents growth potential with analyst consensus target of $620.44 and strong historical execution, though elevated valuations (P/E 35.41) and insider selling warrant caution. The stock's upside depends on continued earnings delivery amid competitive medical services landscape.
VWO trades at $59.67, down 0.3% with a bearish technical signal from moving averages. The ETF faces mixed sentiment as AI-driven Taiwan exposure provides strength while China's economic slowdown weighs on performance. Recent news highlights institutional accumulation with Allianz and Alamar Capital increasing positions, though comparisons show developed market ETFs like VEA offer lower expense ratios and higher yields.
Outlook remains cautious with technical resistance at $60 and support at $59. Emerging markets face headwinds from China's weak retail and property sectors, though AI infrastructure spending offers partial offset. Investors should monitor dollar weakness as a potential catalyst for EM equities while weighing concentration risks in single-country exposures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →About Vanguard Emerging Markets Stock Index Fund ETF
The fund employs an indexing investment approach designed to track the performance of the FTSE Emerging Markets All Cap China A Inclusion Index. It invests by sampling the index, meaning that it holds a broadly diversified collection of securities that, in the aggregate, approximates the index in terms of key characteristics.
Read more on VWO →
